Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-548,367
Closed -$2.48M 5990
2025
Q4
$2.48M Buy
548,367
+105,043
+24% +$538K ﹤0.01% 3899
2025
Q3
$2.39M Buy
443,324
+347,854
+364% +$1.88M ﹤0.01% 4668
2025
Q2
$518K Buy
95,470
+87,211
+1,056% +$346K ﹤0.01% 5686
2025
Q1
$22.9K Buy
8,259
+3,168
+62% +$11K ﹤0.01% 6940
2024
Q4
$17.4K Sell
5,091
-7,723
-60% -$22.3K ﹤0.01% 6873
2024
Q3
$37.7K Buy
12,814
+3,012
+31% +$9.92K ﹤0.01% 6623
2024
Q2
$33.3K Sell
9,802
-12,137
-55% -$39.7K ﹤0.01% 6619
2024
Q1
$66.5K Buy
21,939
+2,868
+15% +$10.1K ﹤0.01% 6420
2023
Q4
$80.3K Buy
19,071
+7,434
+64% +$40.3K ﹤0.01% 6463
2023
Q3
$79.5K Sell
11,637
-2,500
-18% -$22.1K ﹤0.01% 6342
2023
Q2
$147K Sell
14,137
-142,267
-91% -$1.27M ﹤0.01% 6029
2023
Q1
$1.09M Buy
156,404
+96,917
+163% +$845K ﹤0.01% 4835
2022
Q4
$359K Buy
59,487
+48,164
+425% +$356K ﹤0.01% 5601
2022
Q3
$89K Sell
11,323
-49,051
-81% -$572K ﹤0.01% 6396
2022
Q2
$822K Buy
60,374
+30,705
+103% +$508K ﹤0.01% 5072
2022
Q1
$582K Sell
29,669
-43,216
-59% -$863K ﹤0.01% 5727
2021
Q4
$2.5M Buy
72,885
+51,856
+247% +$2.09M ﹤0.01% 4335
2021
Q3
$1.15M Sell
21,029
-9,610
-31% -$579K ﹤0.01% 4933
2021
Q2
$2.25M Buy
30,639
+14,804
+93% +$1.48M ﹤0.01% 4221
2021
Q1
$1.45M Sell
15,835
-11,196
-41% -$1.09M ﹤0.01% 4516
2020
Q4
$2.19M Buy
27,031
+13,147
+95% +$1.01M ﹤0.01% 3874
2020
Q3
$646K Buy
+13,884
New +$775K ﹤0.01% 4525

Bank of America's CVAC Position: Q1 2026 in Review

Bank of America sold out of CureVac (CVAC) in Q1 2026, closing a stake of 548,367 shares — an estimated $2.48M sold.

Bank of America first reported a position in CVAC in Q3 2020 and held it in 22 quarters. The position peaked at $2.5M in Q4 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

  • Bank of America reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 548,367 CureVac shares in Q1 2026, an estimated $2.48M.
  • Bank of America first reported a position in CureVac in Q3 2020 and held it in 22 quarters.
  • Bank of America's CureVac position peaked at $2.5M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.